NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Vildagliptin
Drug: Placebo

First Posted Date: 2008-03-28

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis

Target Recruit Count: 525

Registration Number: NCT00646542

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Cell culture-derived influenza subunit vaccine (cTIV)
Biological: Egg derived influenza subunit vaccine (eTIV)

First Posted Date: 2008-03-27

Last Posted Date: 2015-11-23

Lead Sponsor: Novartis

Target Recruit Count: 3604

Registration Number: NCT00645411

Locations: 🇭🇷
Site 43: Spec. Pediatric Dispensary, Sisak, Croatia
🇫🇮
Site 67: Lahden rokotetutkimusklinikka, Lahti, Finland
🇫🇮
Site 68: Porin rokotetutkimusklinikka, Pori, Finland

and more 57 locations

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: Adjuvanted trivalent inactivated subunit influenza vaccine
Biological: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
Biological: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine

First Posted Date: 2008-03-26

Last Posted Date: 2015-09-18

Lead Sponsor: Novartis

Target Recruit Count: 4902

Registration Number: NCT00644059

Locations: 🇫🇮
East Vantaa Clinic, East Vaanta, Finland
🇫🇮
Jarvenpaa Vaccine Research Clinic, Jarvenpaa, Finland
🇫🇮
Kokkola Vaccine Research Clinic, Kokkola, Finland

and more 98 locations

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

Phase 4

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Carbidopa/levodopa/entacapone
Drug: Immediate release carbidopa/levodopa

First Posted Date: 2008-03-25

Last Posted Date: 2011-02-18

Lead Sponsor: Novartis

Target Recruit Count: 14

Registration Number: NCT00642356

Locations: 🇺🇸
University of California, Irvine, California, United States
🇺🇸
Central New York Research Corporation, Syracuse, New York, United States
🇺🇸
Sunrise Clinical Research, Inc, Hollywood, Florida, United States

and more 18 locations

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Phase 4

Completed

Conditions: Asthma

Interventions: Biological: omalizumab

First Posted Date: 2008-03-20

Last Posted Date: 2016-09-29

Lead Sponsor: Novartis

Target Recruit Count: 48

Registration Number: NCT00639691

Locations: 🇨🇦
Novartis Investigative Site, Montreal, Quebec, Canada

Safety of Lumiracoxib in Patients With Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Device: lumiracoxib
Drug: rofecoxib

First Posted Date: 2008-03-18

Last Posted Date: 2008-03-18

Lead Sponsor: Novartis

Target Recruit Count: 309

Registration Number: NCT00637949

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 300μg
Drug: Placebo

First Posted Date: 2008-03-17

Last Posted Date: 2011-08-30

Lead Sponsor: Novartis

Target Recruit Count: 27

Registration Number: NCT00636961

Locations: 🇩🇪
Novartis Investigator Site, Wiesbaden, Germany

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Phase 1

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Vildagliptin

First Posted Date: 2008-03-12

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis

Target Recruit Count: 22

Registration Number: NCT00633997

Locations: 🇺🇸
Novartis Investigator Site, Baltimore, Maryland, United States

Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin

Phase 3

Completed

Conditions: Pseudomonas Infections

Interventions: Drug: tobramycin

First Posted Date: 2008-03-12

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis

Target Recruit Count: 50

Registration Number: NCT00634192

Locations: 🇩🇪
Novartis Investigator Site, Munich, Germany
🇩🇪
Novartis Investigator site, Halle/Saale, Germany

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Ramipril
Other: Placebo to Aliskiren
Other: Placebo to Ramipril

First Posted Date: 2008-03-10

Last Posted Date: 2011-07-12

Lead Sponsor: Novartis

Target Recruit Count: 774

Registration Number: NCT00631917

Locations: 🇪🇸
Investigative Site, Investigative Site, Spain

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy